🔍

Resonance Specialties Ltd (524218)

📊 BSE: 524218 🏢 Specialty Chemicals 📢 Latest filing: 26 Aug 2026 📝 Analysis written: 13 Nov 2025

Q2 FY27 results

📅 Next results: 30 Oct 2026 (board meeting)

Resonance Specialties Ltd's board meets on 30 Oct 2026 to consider its Q2 FY27 results (July-September 2026).

In its latest reported quarter, Q1 FY27, Resonance Specialties' revenue was ₹32.6 Cr (+53.2% year on year, +33.1% on the previous quarter), and net profit ₹5.7 Cr (+252.4% year on year); the operating margin was 22.9%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹32.6	+53.2%	+33.1%
Operating profit	₹7.5	+192.6%	+32.3%
Net profit	₹5.7	+252.4%	+24.9%
EPS (₹)	4.98	+253.2%	+25.1%
Operating margin	22.9%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

CRISIL Reaffirms 'CRISIL BBB-/Stable' Rating for Rs 14 Cr Bank Loan Facilities

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Aug 2026, 03:30 PM

CRISIL has reaffirmed its 'CRISIL BBB-/Stable' credit rating for Resonance Specialties Ltd's bank loan facilities totaling Rs 14 crore. The rated limits consist of a working capital facility of Rs 12 crore and proposed fund-based bank limits of Rs 2 crore. With the company's low current debt of Rs 2 crore and net worth of Rs 74 crore (debt-to-equity ratio of 0.03), the reaffirmation reflects ongoing stability in servicing obligations and access to banking channels.

Total bank loan facilities rated at Rs 14 Crore
Long-term credit rating reaffirmed at CRISIL BBB-/Stable
Working capital facility rated at Rs 12 Crore
Proposed fund-based bank limits rated at Rs 2 Crore

💡 Monitor working capital utilization and upcoming quarterly earnings performance; no immediate operational action is required.

Rs 29.98 Cr Acquisition & 252% PAT Growth in Q1 FY27 for Resonance Specialties

🟢 POSITIVE ⭐ 9/10

M&A 📅 04 Aug 2026, 12:15 PM

Resonance Specialties reported a robust Q1 FY27 with revenue growing 53% YoY to Rs 32.58 Cr and PAT surging 252% to Rs 5.74 Cr, driven by a 118% jump in export revenue. The company also announced the acquisition of a WHO-Geneva approved manufacturing unit in Mandideep from a promoter group company for Rs 29.98 Cr. This unit previously manufactured intermediates for the company on a job-work basis; internalizing it is expected to enhance operational control and eliminate outsourcing costs. The acquisition value is significant, representing approximately 40% of the company's net worth.

Net Profit for Q1 FY27 surged 252% YoY to Rs 5.74 Cr from Rs 1.63 Cr in the previous year
Acquisition of a manufacturing facility from related party Kaygee Laboratories for Rs 29.98 Cr
Export revenue (Outside India) grew 118% YoY to Rs 23.26 Cr in Q1 FY27
Acquisition includes 22,304 sq. mtrs of leasehold land and WHO-Geneva approved API manufacturing facilities
Conversion charges for the quarter stood at Rs 3.32 Cr, which the acquisition aims to internalize

💡 Monitor the completion of the slump sale by the November 30, 2026 deadline and track the subsequent improvement in operating margins as job-work costs are eliminated.

Resonance Specialties Q1 PAT Jumps 252% YoY; to Acquire ₹29.98 Cr Facility

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 04 Aug 2026, 12:11 PM

Resonance Specialties reported a robust Q1 FY27 with revenue growing 53.2% YoY to ₹32.58 Cr and Net Profit surging 252% YoY to ₹5.74 Cr. Alongside results, the company announced the acquisition of a manufacturing facility in Mandideep, MP, from a related party for ₹29.98 Cr. This facility, which the company previously used on a job-work basis, is WHO-Geneva approved and will help eliminate outsourcing costs. The acquisition value is significant, representing approximately 33% of the company's TTM revenue and 40% of its net worth.

Net Profit for Q1 FY27 rose to ₹5.74 Cr from ₹1.63 Cr in the same quarter last year.
Revenue from operations increased to ₹32.58 Cr, driven by a 118% surge in export revenue to ₹23.26 Cr.
Proposed acquisition of a manufacturing unit from Kaygee Laboratories (Related Party) for ₹29.98 Cr on a slump sale basis.
The target facility includes 22,304 sq. mtrs. of leasehold land and is already WHO-Geneva approved.
Earnings per share (EPS) for the quarter stood at ₹4.98, compared to ₹1.41 in Q1 FY26.

💡 Investors should monitor the shareholder approval process for the related-party acquisition and the subsequent impact on operating margins as the company moves from job-work to in-house manufacturing.

Rs 29.98 Cr Acquisition & 53% Revenue Growth in Q1 FY27 for Resonance Specialties

🟢 POSITIVE ⭐ 9/10

M&A 📅 04 Aug 2026, 12:08 PM

Resonance Specialties reported a strong Q1 FY27 with revenue growing 53% YoY to Rs 32.58 Cr and PAT surging 252% YoY to Rs 5.74 Cr. The board approved the acquisition of a WHO-Geneva approved manufacturing facility in Mandideep from a related party for Rs 29.98 Cr on a slump sale basis. This acquisition represents approximately 40.5% of the company's net worth and aims to internalize production currently handled via job-work. The transaction is expected to close by November 30, 2026, pending shareholder approval.

Q1 FY27 Revenue increased 53.2% YoY to Rs 32.58 Cr from Rs 21.27 Cr in Q1 FY26
Net Profit for the quarter jumped to Rs 5.74 Cr, a 252% increase from Rs 1.63 Cr YoY
Acquisition of Mandideep facility for Rs 29.98 Cr, equivalent to ~33% of TTM Revenue
Export revenue grew 118% YoY to Rs 23.26 Cr, now accounting for 71% of total revenue
Acquired facility includes 22,304 sq. mtrs. of leasehold land and is WHO-Geneva approved

💡 Investors should monitor the shareholder voting outcome for this related-party transaction and track the margin profile post-acquisition to see if internalizing production improves OPM beyond the current 15.5%.

August 4 Board Meeting to Consider Q1 FY27 Financial Results

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 23 Jul 2026, 05:09 PM

Resonance Specialties Ltd has scheduled a board meeting for August 4, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The company enters this reporting period following a strong March 2026 quarter, which saw revenue of ₹24.48 crore and a net profit of ₹4.6 crore. The trading window for insiders has been closed since June 30, 2026, as per SEBI regulations. Investors will be monitoring if the company can maintain its TTM operating profit margin of 15.5% and continue its sequential revenue growth trend.

Board meeting scheduled for August 4, 2026, to approve Q1 results.
Financial results pertain to the quarter ended June 30, 2026.
Trading window closed from June 30, 2026, until 48 hours after the results declaration.
Company reported a TTM PAT of ₹10 crore against a market cap of ₹157 crore.
Sequential revenue has grown from ₹21.27 crore in June 2025 to ₹24.48 crore in March 2026.

💡 Monitor the official results release on August 4 to evaluate if the company sustains its 20% ROCE and low debt-to-equity ratio of 0.03.

Resonance Specialties to Hold 37th AGM on August 4, 2026; Cut-off Date July 28

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 11 Jul 2026, 03:23 PM

Resonance Specialties Ltd has announced its 37th Annual General Meeting (AGM) scheduled for August 4, 2026, at 12:30 PM via video conferencing. The company has dispatched letters to shareholders without registered email addresses, providing access to the FY 2025-26 Annual Report. July 28, 2026, has been fixed as the cut-off date for determining shareholder eligibility for electronic voting. This is a standard regulatory procedure for annual corporate governance and financial reporting.

37th Annual General Meeting scheduled for August 4, 2026, at 12:30 p.m. IST
Cut-off date for e-voting eligibility set for July 28, 2026
Annual Report for the Financial Year 2025-26 is now available on the company website
Meeting to be conducted through Video Conferencing/Other Audio-Visual Means (VC/OAVM)

💡 Investors should download and review the FY 2025-26 Annual Report from the company's website to evaluate financial performance and management commentary before the July 28 voting cut-off.

Resonance Specialties FY26 PAT Grows 58% to ₹10.40 Cr; Proposes 10% Dividend

🟢 POSITIVE ⭐ 6/10

EARNINGS 📅 09 Jul 2026, 10:46 AM

Resonance Specialties reported a strong financial performance for FY 2025-26, with total income rising 16.6% YoY to ₹91.89 Cr. Profit After Tax (PAT) saw a significant jump of 58.3%, reaching ₹10.40 Cr compared to ₹6.57 Cr in the previous year. The company has proposed a 10% dividend and demonstrated improved capital efficiency, with Return on Equity (ROE) increasing from 12% to 16%. A key agenda for the upcoming AGM is the approval of related party transactions up to ₹40 Cr.

Total Income increased to ₹9,188.93 Lacs in FY26 from ₹7,878.69 Lacs in FY25
Profit After Tax (PAT) grew by 58.3% YoY to ₹1,039.58 Lacs
Proposed dividend of 10% amounting to a total payout of ₹115.44 Lacs
Debt-Equity ratio improved by 42%, falling to 0.032 from 0.055
Seeking shareholder approval for related party transactions with Kaygee Laboratories up to ₹40 Cr

💡 Investors should monitor the AGM on August 4, 2026, specifically for the approval and terms of the ₹40 Cr related party transaction, which represents a significant portion of annual revenue.

10% Dividend Recommended; 37th AGM Scheduled for August 4, 2026

🟢 POSITIVE ⭐ 5/10

DIVIDEND 📅 07 Jul 2026, 06:25 PM

Resonance Specialties Ltd has announced its 37th Annual General Meeting (AGM) for August 4, 2026. The Board has recommended a dividend of Re. 1 per equity share (10% of face value) for the financial year ended March 31, 2026. The record date for determining dividend eligibility is July 28, 2026, with payment expected by August 28, 2026. Shareholders can participate in remote e-voting between July 31 and August 3, 2026.

Dividend of Re. 1 per share recommended, representing 10% of the Rs. 10 face value.
Record date for dividend entitlement fixed as July 28, 2026.
37th Annual General Meeting scheduled for August 4, 2026, at 12:30 p.m. via VC/OAVM.
Remote e-voting period set from July 31, 2026 (9:00 a.m.) to August 3, 2026 (5:00 p.m.).
Dividend payment to be completed on or before August 28, 2026, subject to shareholder approval.

💡 Investors should review the FY 2025-26 Annual Report available on the company website for detailed financial performance and management outlook before the AGM.

View All 524218 Announcements on Live Market Tracking →